Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies [0.03%]
浆细胞样树突状细胞肿瘤的治疗手段：异基因造血细胞移植和新型疗法
Mohamed A Kharfan-Dabaja,Naveen Pemmaraju,Mohamad Mohty
Mohamed A Kharfan-Dabaja
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells. There is no established standard therapy for BPDCN and the efficacy of conventio...
Clinical Hematology International: Why a New Journal in Hematology? [0.03%]
临床血液学国际：为什么要在血液病领域出版一种新杂志？
Mohamad Mohty,Arnon Nagler,Bipin Savani
Mohamad Mohty
Anas Zahid,Elizabeth L Siegler,Saad S Kenderian
Anas Zahid
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refr...
B cell deficiency in patients with relapsed and refractory acute myeloid leukemia [0.03%]
复发和难治性急性髓系白血病患者的B细胞缺乏症
Meghali Goswami,Katherine E Lindblad,Rahul Ramraj et al.
Meghali Goswami et al.
Jacob Shreve,Aziz Nazha
Jacob Shreve
Myelodysplastic syndromes (MDSs) are potentially devastating monoclonal deviations of hematopoiesis that lead to bone marrow dysplasia and variable cytopenias. Predicting severity of disease progression and likelihood to undergo acute myelo...
Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia [0.03%]
复发或难治性急性髓系白血病的定时序贯挽救化疗
Bogdan Popescu,Sheenu Sheela,Julie Thompson et al.
Bogdan Popescu et al.
Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a se...